Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $3.6 million.

  • BioXcel Therapeutics' Other Non-Current Liabilities fell 1744.9% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 1744.9%. This contributed to the annual value of $6.6 million for FY2024, which is 24818.9% up from last year.
  • BioXcel Therapeutics' Other Non-Current Liabilities amounted to $3.6 million in Q3 2025, which was down 1744.9% from $2.6 million recorded in Q2 2025.
  • BioXcel Therapeutics' Other Non-Current Liabilities' 5-year high stood at $21.2 million during Q1 2024, with a 5-year trough of $1.9 million in Q3 2022.
  • In the last 4 years, BioXcel Therapeutics' Other Non-Current Liabilities had a median value of $2.6 million in 2023 and averaged $4.7 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 72447.55% in 2024, then crashed by 8457.26% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Other Non-Current Liabilities stood at $2.3 million in 2022, then decreased by 18.69% to $1.9 million in 2023, then skyrocketed by 248.19% to $6.6 million in 2024, then plummeted by 45.65% to $3.6 million in 2025.
  • Its Other Non-Current Liabilities stands at $3.6 million for Q3 2025, versus $2.6 million for Q2 2025 and $3.3 million for Q1 2025.